How to Write an Appeal Letter That Actually Gets Your Prior Auth Approved
How to Write an Appeal Letter That Actually Gets Your Prior Auth Approved
Most appeal letters fail before the reviewer reads the second paragraph.
Not because the clinical case is weak. Because the letter repeats the same documentation that already failed — just formatted differently. The payer sees it dozens of times a week. The reviewer knows immediately when nothing new is being offered.
An effective appeal isn't a louder version of the original request. It's a direct, structured response to the specific reasons the payer denied the case — with new evidence attached.
What the Data Says About Appeal Success Rates
The success rate on prior auth appeals is genuinely encouraging — if you know what you're doing.
KFF analysis of Medicare Advantage data found that enrollees who appealed PA denials won more than 80% of the time in some plan categories. The HHS Office of Inspector General documented that MA plans overturned 75% of their own denials on appeal — which raises the obvious question of why those cases were denied in the first place.
The answer is almost always documentation. The clinical need was real from day one. The first submission just didn't make the case adequately.
That gap is where a well-constructed appeal lives.
Read the Denial Letter. Actually Read It.
This sounds obvious. It isn't how most practices operate.
The denial letter contains the specific criteria the payer claims aren't met. Most appeal writers skim this and write a general letter defending the treatment choice. That's the wrong approach.
The denial letter is your outline. Every stated reason for denial becomes a section in your appeal. If the letter says "no documentation of inadequate response to conventional therapy," your appeal needs a section that directly addresses inadequate response to conventional therapy — with dates, doses, and documented outcomes.
Payer denial letters often cite the specific policy document and policy number they're applying. Look up that document. Read the criteria language. Your appeal should use the same terminology the policy uses — not your clinical shorthand, not generic medical language, but the payer's own criteria language mapped to your patient's case.
The Framework: What Every Strong Appeal Needs
Strong appeals follow a consistent structure. Here's the framework:
Opening paragraph: State the request and the denial. One or two sentences. "We are appealing the denial of [drug name] for [patient initials], denied on [date] under reference number [X], on the grounds that [cite the stated denial reason]."
Section 1: Address each denial reason directly. One section per stated denial reason. Don't combine them. Each one gets a heading, a direct statement that the criterion is met, and the specific evidence supporting that statement.
Section 2: Clinical summary. Concise overview of the patient's diagnosis, disease severity (with validated scoring tools — DAS28, PASI, CDAI, BASDAI, depending on condition), and treatment history. This contextualizes the evidence in Section 1.
Section 3: Prior treatment documentation. Every prior therapy tried should be listed with: drug name, dose, duration, and documented reason for discontinuation (inadequate response, adverse effect, or contraindication). Dates matter. "Patient tried methotrexate for 6 months at 20mg/week and discontinued due to inadequate response documented on [date]" is evidence. "Patient tried methotrexate" is not.
Section 4: Supporting literature. Include published clinical guidelines or peer-reviewed studies that support your treatment choice. One to three citations is sufficient — more risks burying the argument. Cite the specific relevant passage, not just the study title.
Closing: State the specific action requested. "We respectfully request approval of [drug] at [dose] for [duration]." Don't end vague.
Attachments. List every document attached: relevant chart notes, lab results, prior treatment records, the published guidelines cited. The appeal letter argues the case; the attachments prove it.
What Not to Do
These mistakes appear in the majority of appeal letters that get upheld — meaning the denial stands:
Restating the original submission. If the first submission said "patient has inadequate response to methotrexate" and the appeal says "patient has inadequate response to methotrexate," nothing changed. The reviewer upholds.
Emotional framing. Phrases like "my patient is suffering" or "this delay is causing significant distress" are understandable expressions of genuine clinical concern. They do not move payer reviewers. Clinical evidence does. Keep the language factual.
Missing deadlines. Most payers allow 60-180 days from denial to file a first-level appeal. Many providers don't realize that internal appeal rights often must be exhausted before external review or state commissioner complaint options become available. Miss the deadline and you lose the right. Calendar it immediately when the denial arrives.
Appealing to the wrong level. First-level appeals go to the plan's internal review. Second-level appeals (if the first fails) may go to an independent external review organization. Some providers skip to external review before exhausting internal options, which can create procedural problems. Know the payer's specific appeal hierarchy before you submit.
One generic letter for all payers. Aetna's clinical coverage policy for a given biologic may differ significantly from UnitedHealthcare's. A letter that maps your patient's case to Aetna's criteria may not address United's at all. Each appeal needs to be written against the specific payer's specific policy.
A Note on Evidence That Actually Moves the Needle
Experienced appeal writers know that certain types of supporting evidence perform better than others.
Validated clinical scores beat narrative descriptions. "Patient has severe disease activity as evidenced by DAS28 of 5.8" is stronger than "patient has severe RA." Payers build their criteria around validated scores for exactly this reason.
Documented adverse effects beat assumed ones. If a patient couldn't tolerate a first-line therapy, the chart note documenting the adverse effect needs to be in the file — not inferred. A note that says "patient switched from methotrexate due to GI intolerance, documented as nausea grade 2 on [date]" is evidence. A note that says "patient on adalimumab" with no prior therapy documentation creates the gap that generates the denial.
Major society guidelines carry weight. ACR, AAD, and other specialty society guidelines are generally respected by payer clinical reviewers because they represent consensus expert opinion. If your treatment choice aligns with current society guidelines, say so explicitly and attach the relevant excerpt.
Published clinical literature supports but doesn't replace the clinical argument. A study showing 60% response rate for your drug in patients meeting specific criteria is useful context. It doesn't substitute for demonstrating your specific patient meets those criteria.
The Expedited Appeal Track
When a patient's condition is urgent — where delay would seriously jeopardize health or ability to function — an expedited appeal is available under CMS rules for MA plans. The timeline is 72 hours. State-regulated commercial plans have similar provisions, with timelines varying by state.
The bar for "urgent" is meant to be clinical, not administrative inconvenience. Document the urgency with specifics: current disease activity score, risk of disease progression, functional limitations, or clinical risks of delay. A generic "urgent" request without clinical justification usually gets downgraded to standard review.
External Review: When Internal Appeals Fail
If internal appeals are exhausted and upheld, most patients have the right to an independent external review through an Independent Review Organization (IRO). The CMS external review framework applies to most non-grandfathered health plans. State insurance departments administer the process in most cases.
External review overturn rates are lower than internal appeal rates, but they're not negligible. For biologic denials involving complex chronic conditions, a well-documented external review submission — with the full appeal record, supporting literature, and a clear clinical argument — can succeed even after two internal denial decisions.
The Upstream Solution
Here's the honest take: a well-constructed appeal is expensive. Physician time to prepare, staff time to track, administrative overhead to manage. The average PA appeal costs a practice $77-200 in staff time depending on complexity — and that's before counting the cost of delayed treatment to the patient.
The real goal is reducing how often you need to write appeals at all. Documentation quality on the initial submission is the only reliable way to do that. When the first PA request addresses every payer criterion with specific clinical evidence — validated scores, documented prior treatment history, lab values in context — denial rates drop sharply.
AJMC research found that practices with structured PA documentation workflows had meaningfully lower denial rates than those relying on unstructured or template-based submissions. The investment in documentation quality up front pays back in fewer appeals, faster approvals, and patients who get treated on schedule.
When you do need to write an appeal — and you will — the framework above works. But the best appeal letter is the one you never had to write.
Sources:
Kaiser Family Foundation. (2024). Medicare Advantage Appeal Outcomes and Audit Findings. kff.org
HHS Office of Inspector General. (2022). Medicare Advantage Organization Denials of Prior Authorization Requests. oig.hhs.gov
Centers for Medicare & Medicaid Services. (2024). External Review and Independent Review Organizations. cms.gov
American Journal of Managed Care. (2023). Prior Authorization Burden and Workarounds in Primary Care. ajmc.com
American Medical Association. (2025). Prior Authorization Reform — Appeal Process Guidance. ama-assn.org